Amgen and Zai Lab have agreed to run a global clinical trial combining two DLL3 targeted therapies for small cell lung cancer ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: ...
Zai Lab (ZLAB) stock jumps as the company announces a global clinical trial collaboration with Amgen (AMGN). Read more here.
Zai Lab and Amgen will collaborate on a clinical trial to evaluate a Zai Lab lung cancer therapy. Under the agreement, Amgen will sponsor a global phase 1b study to evaluate the safety and efficacy of ...
Amgen (NASDAQ:AMGN) stock dipped on Wednesday following an update from its partner, Zai Lab (NASDAQ:ZLAB), regarding the late-stage trial of bemarituzumab combined with chemotherapy for gastric cancer ...
Zai Lab (09688.HK) announced that it has entered into a global clinical research collaboration with Amgen (AMGN.US) to ...
Zacks Investment Research on MSN
Is Amgen (AMGN) outperforming other medical stocks this year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Amgen (AMGN) one of those stocks right now? A quick glance at ...
At Amgen, science and purpose go hand in hand. The company’s mission, which is to serve patients, is at the heart of everything it does. The company harnesses the best of biology and technology to ...
Amgen Inc (NASDAQ:AMGN) on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab plus chemotherapy (mFOLFOX6). The study met its primary endpoint of overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results